{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=2&q=relapsed+refractory+myeloma", "query": { "q": "relapsed refractory myeloma", "condition": "Multiple Myeloma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=1&q=relapsed+refractory+myeloma&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T21:04:15.018Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02948283", "title": "Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anemia", "Fatigue", "Fever", "Lymphadenopathy", "Lymphocytosis", "Night Sweats", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Plasma Cell Myeloma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Plasma Cell Myeloma", "Splenomegaly", "Thrombocytopenia", "Weight Loss" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Metformin Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Quality-of-Life", "type": "OTHER" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-09-05", "completion_date": "2017-12-01", "has_results": false, "last_update_posted_date": "2021-02-12", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948283" }, { "nct_id": "NCT02765854", "title": "Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2016-09-01", "completion_date": "2023-05-23", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Ann Arbor, Michigan • St Louis, Missouri", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02765854" }, { "nct_id": "NCT02109224", "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult B Acute Lymphoblastic Leukemia", "Chronic Lymphocytic Leukemia", "Cutaneous B-Cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "HIV Infection", "Intraocular Lymphoma", "Multicentric Angiofollicular Lymphoid Hyperplasia", "Nodal Marginal Zone Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Plasma Cell Myeloma", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2014-09", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-08-20", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 7, "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109224" }, { "nct_id": "NCT05172596", "title": "PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "PHE885", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 146, "start_date": "2022-03-03", "completion_date": "2025-05-21", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 6, "location_summary": "Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05172596" }, { "nct_id": "NCT05391750", "title": "Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-10-19", "completion_date": "2028-02-12", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05391750" }, { "nct_id": "NCT06550895", "title": "A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2024-09-16", "completion_date": "2027-08-26", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 5, "location_summary": "Iowa City, Iowa • Louisville, Kentucky • Detroit, Michigan + 2 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06550895" }, { "nct_id": "NCT03871829", "title": "Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib 20 mg/m^2", "type": "DRUG" }, { "name": "Carfilzomib 70 mg/m^2", "type": "DRUG" }, { "name": "Dexamethasone 40 mg", "type": "DRUG" }, { "name": "Dara-SC 1800 mg", "type": "DRUG" }, { "name": "Dexamethasone 20 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2019-05-31", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 11, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Whittier, California + 8 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Whittier", "state": "California" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03871829" }, { "nct_id": "NCT00639002", "title": "A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ruxolitinib 25 mg", "type": "DRUG" }, { "name": "Dexamethasone 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2008-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 3, "location_summary": "Highland, California • Boynton Beach, Florida • New York, New York", "locations": [ { "city": "Highland", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00639002" }, { "nct_id": "NCT02757326", "title": "ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Opaganib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RedHill Biopharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2016-12-13", "completion_date": "2019-05", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02757326" }, { "nct_id": "NCT02188368", "title": "Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "POM", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" }, { "name": "CFZ", "type": "DRUG" }, { "name": "BTZ", "type": "DRUG" }, { "name": "CLA", "type": "DRUG" }, { "name": "CY", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-07-07", "completion_date": "2020-10-23", "has_results": false, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-07-23T21:04:15.018Z", "location_count": 12, "location_summary": "Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188368" } ] }